Anacor Pharmaceuticals to Present at Deutsche Bank’s 39th Annual Health Care Conference

  Anacor Pharmaceuticals to Present at Deutsche Bank’s 39th Annual Health Care

Deutsche Bank 39th Annual Health Care Conference

Business Wire

PALO ALTO, Calif. -- May 1, 2014

Anacor Pharmaceuticals, Inc. (NASDAQ:ANAC) announced today that Paul Berns,
the company’s President and Chief Executive Officer, will provide a company
overview at Deutsche Bank’s 39th Annual Health Care Conference on Thursday,
May 8, 2014 at 10:40 a.m. ET in Boston, Massachusetts. The event will be
webcast live and may be accessed under “Events and Presentations” on the
Investors page of Anacor’s website at A replay will also be
available for three months following the presentation.

About Anacor Pharmaceuticals

Anacor is a biopharmaceutical company focused on discovering, developing and
commercializing novel small-molecule therapeutics derived from its boron
chemistry platform. Anacor has discovered eight compounds that are currently
in development. Its two lead product candidates are topically administered
dermatologic compounds — tavaborole, an antifungal for the treatment of
onychomycosis, and AN2728, an anti-inflammatory PDE-4 inhibitor for the
treatment of atopic dermatitis and psoriasis. In addition to its two lead
programs, Anacor has discovered three other wholly-owned clinical product
candidates — AN2718 and AN2898, which are backup compounds to tavaborole and
AN2728, respectively, and AN3365, an antibiotic for the treatment of
infections caused by Gram-negative bacteria. Anacor has also discovered three
other compounds that have been out-licensed for further development — one is
licensed to Eli Lilly and Company for the treatment of an animal health
indication, the second compound, AN5568, also referred to as SCYX-7158, is
licensed to Drugs for Neglected Diseases initiative, or DNDi, for human
African trypanosomiasis (HAT, or sleeping sickness) and the third compound is
licensed to GlaxoSmithKline, LLC for development in tuberculosis. Anacor also
has a pipeline of other internally discovered topical and systemic boron-based
compounds in development. For more information, visit


DeDe Sheel, 650-543-7575
Senior Director, Investor Relations and Corporate Communications
Press spacebar to pause and continue. Press esc to stop.